Articles dans des revues avec comité de lecture (84)
49.
Le Mercier, M., D'Haene, N., Rorive, S., Degand, C., De Nève, N., & Salmon, B. O. (2016). Next generation sequencing : Une nouvelle technologie pour améliorer le diagnostic des cancers thyroïdiens. Revue médicale de Bruxelles, 37(5), 436-438.50.
Solassol, J., Le Mercier, M., Grauslund, M., Melchior, L. C., Burt, E., Cotter, F., Stieber, D., De Lander Schmitt, F., Motta, V., Lauricella, C., Colling, R., Vendrell, J., Soilleux, E., Fassan, M., Mescoli, C., Collin, C., Pagès, J. C., Sillekens, P., Märkl, B., Haas, C., Bellosillo, B., Montagut, C., Smith, M., O'Sullivan, B., & D'Haene, N. (2016). Multi-center evaluation of the fully automated PCR-based Idylla™ KRAS mutation assay for rapid KRAS mutation status determination on formalin-fixed paraffin-embedded tissue of human colorectal cancer. PloS one, 11(9), e0163444. doi:10.1371/journal.pone.016344451.
Rosoux, A., Ocak, S., Pauwels, P., Duplaquet, F., D'Haene, N., Weynand, B., Delos, M., Menon, R., Heukamp, L. C. A. L., & Thunnissen, E. (2016). Effectiveness of crizotinib in a patient with ALK IHC-positive/FISH-negative metastatic lung adenocarcinoma. Lung cancer, 98, 118-121. doi:10.1016/j.lungcan.2016.06.00152.
Koopmansch, C., D'Haene, N., Hastir, D., Sadeghi-Meibodi, N., Maris, C., & Salmon, I. (2016). A 63-Year-Old Woman with a Right Frontal Lesion. Brain pathology, 26(4), 555-556. doi:10.1111/bpa.1239353.
D'Haene, N., Blanchard, O., De Nève, N., Evens, J., Maris, C., Rorive, S., Le Mercier, M., & Salmon, I. (2016). Comment la biologie moléculaire améliore le diagnostic clinique des gliomes? Revue médicale de Bruxelles, 37(3), 152-158.54.
Duerinck, J., Bouttens, F., Verschaeve, V., Neyns, B., Du Four, S., Vandervorst, F., D'Haene, N., Le Mercier, M., Michotte, A., Van Binst, A., Everaert, H., & Salmon, I. (2016). Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma. Journal of neuro-oncology, 128(1), 147-155. doi:10.1007/s11060-016-2092-255.
D'Haene, N., Demetter, P., Tejpar, S., Salmon, I., Le Mercier, M., De Nève, N., Blanchard, O., Delaunoy, M., El Housni, H., Dessars, B., Heimann, P., & Remmelink, M. (2015). Clinical validation of targeted next generation sequencing for colon and lung cancers. PloS one, 10(9), e0138245. doi:10.1371/journal.pone.013824556.
Maris, C., D'Haene, N., Trepant, A.-L., Le Mercier, M., Sauvage, S., Allard, J., Rorive, S., Demetter, P., Decaestecker, C., & Salmon, I. (2015). IGF-IR: a new prognostic biomarker for human glioblastoma. British Journal of Cancer, 113(5), 729-737. doi:10.1038/bjc.2015.24257.
Le Mercier, M., D'Haene, N., De Nève, N., Blanchard, O., Degand, C., Rorive, S., & Salmon, I. (2015). Next-generation sequencing improves the diagnosis of thyroid FNA specimens with indeterminate cytology. Histopathology, 66(2), 215-224. doi:10.1111/his.1246158.
D'Haene, N., Maris, C., Rorive, S., Decaestecker, C., Le Mercier, M., & Salmon, I. (2014). Galectins and neovascularization in central nervous system tumors. Glycobiology, 24(10), 892-898. doi:10.1093/glycob/cwu04959.
D'Haene, N., Sauvage, S., Maris, C., Adanja, I., Le Mercier, M., Decaestecker, C., Baum, L., & Salmon, I. (2013). VEGFR1 and VEGFR2 Involvement in Extracellular Galectin-1- and Galectin-3-Induced Angiogenesis. PloS one, 8(6), e67029. doi:10.1371/journal.pone.0067029